Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ausrichter pty ltd - trimethoprim; sulfadiazine - oral bolus + intra vaginal/uterine - trimethoprim pyrimidine active 200.0 mg/tb; sulfadiazine sulfanyl active 1000.0 mg/tb - antibiotic+genitourinary - calf | cow | horse foal | horse mare (female) | pig sow (female) | sheep ewe (female) | beef calf | bovine | calf - poddy | calf - bacterial infection | amoxycillin sensitive bacteria | associated with viral disease | gram negative organisms | gram positive organisms | post parturient bacterial infe | primary bacterial infection | sulfadiazine sensitive bacteri | trimethoprim sensitive bacteri | tylosin sensitive bacteria

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - trimethoprim sulfate (unii: e377mf8eq8) (trimethoprim - unii:an164j8y0x), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k) - trimethoprim 1 mg in 1 ml - trimethoprim sulfate and polymyxin b sulfate ophthalmic solution is indicated in the treatment of surface ocular bacterial infections, including acute bacterial conjunctivitis, and blepharoconjunctivitis, caused by susceptible strains of the following microorganisms: staphylococcus aureus, staphylococcus epidermidis, streptococcus pneumoniae, streptococcus viridans, haemophilus influenza and pseudomonas aeruginosa. * *efficacy for this organism in this organ system was studied in fewer than 10 infections. trimethoprim sulfate and polymyxin b sulfate ophthalmic solution is contraindicated in patients with known hypersensitivity to any of its components.

United States - English - NLM (National Library of Medicine)

proficient rx lp - trimethoprim sulfate (unii: e377mf8eq8) (trimethoprim - unii:an164j8y0x), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k) - trimethoprim 1 mg in 1 ml - trimethoprim sulfate and polymyxin b sulfate ophthalmic solution is indicated in the treatment of surface ocular bacterial infections, including acute bacterial conjunctivitis, and blepharoconjunctivitis, caused by susceptible strains of the following microorganisms: staphylococcus aureus, staphylococcus epidermidis, streptococcus pneumoniae, streptococcus viridans, haemophilus influenza and pseudomonas aeruginosa. * *efficacy for this organism in this organ system was studied in fewer than 10 infections. trimethoprim sulfate and polymyxin b sulfate ophthalmic solution is contraindicated in patients with known hypersensitivity to any of its components.

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - trimethoprim sulfate (unii: e377mf8eq8) (trimethoprim - unii:an164j8y0x), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k) - trimethoprim 1 mg in 1 ml - trimethoprim sulfate and polymyxin b sulfate ophthalmic solution is indicated in the treatment of surface ocular bacterial infections, including acute bacterial conjunctivitis, and blepharoconjunctivitis, caused by susceptible strains of the following microorganisms: staphylococcus aureus, staphylococcus epidermidis, streptococcus pneumoniae, streptococcus viridans, haemophilus influenza and pseudomonas aeruginosa. * *efficacy for this organism in this organ system was studied in fewer than 10 infections. trimethoprim sulfate and polymyxin b sulfate ophthalmic solution is contraindicated in patients with known hypersensitivity to any of its components.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ausrichter pty ltd - glycine; lysine-l; methionine-dl; hyoscine methobromide; pectin; kaolin light; bismuth subcarbonate; calcium chloride; potassium chloride; magnesium sulfate; sodium acetate; trimethoprim; sulfadiazine; vitamin b2 = riboflavin; vitamin b1 hydrochloride = thiamine hydrochloride - oral tablet - glycine amino acid-glycine active 25.0 mg/100ml; lysine-l amino acid-lysine-l active 12.0 mg/100ml; methionine-dl amino acid-methionine-dl active 20.0 mg/100ml; hyoscine methobromide alkaloid active 10.0 mg/100ml; pectin carbohydrate active 1.38 g/100ml; kaolin light clay active 11.3 g/100ml; bismuth subcarbonate mineral-bismuth active 770.0 mg/100ml; calcium chloride mineral-calcium-salt active 15.0 mg/100ml; potassium chloride mineral-potassium active 20.0 mg/100ml; magnesium sulfate mineral-magnesium active 20.0 mg/100ml; sodium acetate mineral-sodium-salt active 25.0 mg/100ml; trimethoprim pyrimidine active 200.0 mg/100ml; sulfadiazine sulfanyl active 1.0 g/100ml; vitamin b2 = riboflavin vitamin-b2 active 20.0 mg/100ml; vitamin b1 hydrochloride = thiamine hydrochloride vitamin-b1 active 20.0 mg/100ml - alimentary system - calf | cattle | dog | horse | horse foal | beef | beef calf | bitch | bos indicus | bos taurus | bovine | buffalo | bull | bullo - organisms sensitive to sulphadiazine | organisms sensitive to trimethoprim

United States - English - NLM (National Library of Medicine)

lupin pharmaceuticals,inc. - trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - trimethoprim 100 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of trimethoprim tablets, usp and other antibacterial drugs, trimethoprim tablets, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. for the treatment of initial episodes of uncomplicated urinary tract infections due to susceptible strains of the following organisms: escherichia coli , proteus mirabilis , klebsiella pneumoniae , enterobacter species, and coagulase-negative staphylococcus species, including s. saprophyticus . cultures and susceptibility tests should be performed to determine the susceptibility of the bacteria to trimethoprim. therapy may be initiated prior to obtaining the results of these tests. trimethoprim is contraindicated in individuals hypersensitive to trimethoprim and in those with documented megaloblastic anemia due to folate deficiency.

United States - English - NLM (National Library of Medicine)

avkare, inc. - trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - trimethoprim 100 mg - to reduce the development of drug resistant bacteria and maintain the effectiveness of trimethoprim tablets, usp and other antibacterial drugs, trimethoprim tablets, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. for the treatment of initial episodes of uncomplicated urinary tract infections due to susceptible strains of the following organisms: escherichia coli , proteus mirabilis , klebsiella pneumoniae , enterobacter species, and coagulase-negative staphylococcus species, including s. saprophyticus . cultures and susceptibility tests should be performed to determine the susceptibility of

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - trimethoprim 100 mg - for the treatment of initial episodes of uncomplicated urinary tract infections due to susceptible strains of the following organisms: escherichiacoli, proteus mirabilis, klebsiella pneumoniae, enterobacter species and coagulase-negative staphylococcus species, including s. saprophyticus. cultures and susceptibility tests should be performed to determine the susceptibility of the bacteria to trimethoprim. therapy may be initiated prior to obtaining the results of these tests. trimethoprim tablets are contraindicated in individuals hypersensitive to trimethoprim and in those with documented megaloblastic anemia due to folate deficiency.

United States - English - NLM (National Library of Medicine)

mayne pharma - trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - trimethoprim 100 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of trimethoprim tablets, usp and other antibacterial drugs, trimethoprim tablets, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. for the treatment of initial episodes of uncomplicated urinary tract infections due to susceptible strains of the following organisms: escherichia coli , proteus mirabilis , klebsiella pneumoniae , enterobacter species, and coagulase-negative staphylococcus species, including s. saprophyticus . cultures and susceptibility tests should be performed to determine the susceptibility of the bacteria to trimethoprim. therapy may be initiated prior to obtaining the

United States - English - NLM (National Library of Medicine)

novel laboratories, inc. - trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - trimethoprim 100 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of trimethoprim tablets, usp and other antibacterial drugs, trimethoprim tablets, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. for the treatment of initial episodes of uncomplicated urinary tract infections due to susceptible strains of the following organisms: escherichia coli , proteus mirabilis , klebsiella pneumoniae , enterobacter species, and coagulase-negative staphylococcus species, including s. saprophyticus . cultures and susceptibility tests should be performed to determine the susceptibility of the bacteria to trimethoprim. therapy may be initiated prior to obtaining the